Novartis cuts CCO title as international chief Marie-France

Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial offic | Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial officer title.

From the Heart

Recommendations for surveillance of pulmonary dysfunction among childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group - eClinicalMedicine

IJERPH February-2 2022 - Browse Articles

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P182)

What's behind the Novartis job cuts? - SWI

Evidence-based clinical guidelines for immigrants and refugees

2023_Speaker - 12th International mRNA Health Conference

Biomanufacturing World Summit

Companies Investors Start-up projects

Plenary Session 1 - 19th International C. elegans Meeting

Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015

Trademarks Journal Vol. 66 No. 3386